Stover AM, Basak R, Mueller D, Lipman R, et al. Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Non-Muscle-Invasive Bladder Cancer. J Urol 2022 May 31:101097JU0000000000002747. doi: 10.1097/JU.0000000000002747.
PMID: 35640276